A First‑in‑human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors
Trial status:Will Be Recruiting
Trial ID:
BNT3211-01
NCT ID:
EudraCT ID:
N/A
EU Trial (CTIS) Number:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Collaborator:
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Will Be Recruiting
Trial Details
This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.
Medical Condition
Solid Tumors
Study Drug
BNT3211
Phase
Phase 1/Phase 2
Type
Interventional
Estimated Enrolment
345
Estimated Trial Date
Nov 2026 - Oct 2029
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Inclusion and Exclusion Criteria
Inclusion criteria
- Are ≥18 years of age (local laws will be followed if the age of consent is older).
- Have an Eastern Cooperative Oncology Group performance status of 0 to 1.
- Have a life expectancy of ≥3 months in the opinion of the investigator.
- Have at least one measurable lesion as per RECIST v1.1.
- Have an archival formalin-fixed paraffin-embedded tumor tissue sample available or are willing to be biopsied to obtain a fresh tumor tissue sample.
- Have histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors and must have received all available standard of care (SoC) treatment in accordance with local practice (unless the standard therapy is considered inappropriate or intolerable) and failed at least first-line SoC therapy prior to enrollment.
- Have an adequate coagulation, hematologic, and organ function as defined by the protocol.
- Left ventricular ejection fraction (LVEF) ≥50% by either echocardiogram or multi-gated acquisition scan within 28 days prior to first dose of study treatment.
Exclusion criteria
- Have had major surgery (not including diagnostic surgery) within the 4 weeks prior to the first dose of study treatment or are planned to undergo major surgery during the course of the study.
- Have had prior allogeneic bone marrow transplantation or solid-organ transplantation.
- Have had an inadequate washout period for prior anticancer treatment or other restricted medications prior to the first dose of investigational medicinal product (IMP) as defined in the protocol.
- Have received systemic steroids (\>10 mg/day of prednisone or its equivalent) or other immunosuppressive therapy within 2 weeks prior to the first dose of IMP. Protocol defined exceptions apply.
- Have received any live or attenuated vaccine within 4 weeks prior to the first dose of IMP or intend to receive a live or attenuated vaccine during the study.
- Have a history of leptomeningeal carcinomatosis.
- Have brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anticonvulsants for at least 2 weeks prior to the first dose of IMP.
- Have a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Protocol-defined exceptions apply.
- Have clinically significant concomitant pulmonary disease, including but not limited to: chronic obstructive pulmonary disease, restrictive lung disease, lung injury accompanied with autoimmune disease/connective tissue disorders.
- Have uncontrolled pleural effusions, ascites, or pericardial effusions that require repeated drainage (once monthly or more frequently).
- Have active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal conditions that may cause bleeding or perforation in the opinion of the treating investigator.
- Have an active infection that requires systemic therapy (except for oral antibiotics) within 1 week prior to the first dose of IMP. Participants receiving prophylactic anti-infective therapy (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) may be eligible.
- Have active or chronic corneal disorders, or other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.
- Have a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Protocol defined exceptions apply.
- Have any other primary malignancy within 3 years prior to the first dose of IMP, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors.
- Have unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved according to (US) National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Grade ≤1 (unless the investigator determines that certain AEs pose no safety risk to the participant, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy).
- Have any of the following heart conditions within 6 months prior to the study treatment:
- Acute coronary syndrome, coronary artery bypass grafting, congestive heart failure, aortic dissection, stroke, or other Grade 3 and above cardiovascular and cerebrovascular events.
- New York Heart Association functional classification ≥II heart failure or LVEF \<50%.
- Ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, or congenital long QT syndrome. Participants with treated cardiac arrhythmia/atrial fibrillation are allowed.
- Mean QT interval corrected by Fridericia's method \>450 ms for males or \>470 ms for females in three successive screening measurements based on a 12-lead electrocardiogram.
- Unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months.
Note: Other protocol defined inclusion and exclusion criteria apply.
Trial Locations
No locations found.